The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tolinase     1-(azepan-1-yl)-3-(4- methylphenyl)sulfonyl...

Synonyms: Diabewas, Tolamide, Tolanase, Norglycin, Tolazamida, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of tolazamide

  • Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus [1].
  • Therapy with either tolazamide or exogenous insulin resulted in a similar lowering (P less than 0.05) of postabsorptive glucose-production rates (from 2.3 +/- 0.1 to 2.0 +/- 0.2 and 1.8 +/- 0.1 mg per kilogram of body weight per minute, respectively) but not to normal (1.5 +/- 0.1 mg per kilogram per minute) [1].
  • A case of chronic liver disease due to tolazamide [2].
  • After treatment (2--4 wk) with tolazamide (500 mg daily), adherence to the nylon fiber columns employed in this study returned to control levels in the seven patients whose fasting glucose levels fell, (mean, 192 +/- 16 mg/100 ml) and deteriorated in the three in whom fasting hyperglycemia worsened [3].
  • Therefore, adjuvant therapy with tolazamide and insulin may be beneficial in achieving adequate metabolic control in type I diabetes mellitus [4].

Psychiatry related information on tolazamide


High impact information on tolazamide


Chemical compound and disease context of tolazamide


Biological context of tolazamide


Anatomical context of tolazamide


Associations of tolazamide with other chemical compounds


Gene context of tolazamide


Analytical, diagnostic and therapeutic context of tolazamide


  1. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. Firth, R.G., Bell, P.M., Rizza, R.A. N. Engl. J. Med. (1986) [Pubmed]
  2. A case of chronic liver disease due to tolazamide. Nakao, N.L., Gelb, A.M., Stenger, R.J., Siegel, J.H. Gastroenterology (1985) [Pubmed]
  3. Impaired granulocyte adherence in mildly diabetic patients: effects of tolazamide treatment. Bagdade, J.D., Walters, E. Diabetes (1980) [Pubmed]
  4. Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Kabadi, U.M., Birkenholz, M.R. Arch. Intern. Med. (1988) [Pubmed]
  5. Wernicke's encephalopathy induced by tolazamide. Kwee, I.L., Nakada, T. N. Engl. J. Med. (1983) [Pubmed]
  6. In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport. Maloff, B.L., Lockwood, D.H. J. Clin. Invest. (1981) [Pubmed]
  7. Characterization of the sulfonylurea receptor on beta cell membranes. Gaines, K.L., Hamilton, S., Boyd, A.E. J. Biol. Chem. (1988) [Pubmed]
  8. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Karam, J.H., Sanz, N., Salamon, E., Nolte, M.S. Diabetes (1986) [Pubmed]
  9. Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Longnecker, M.P., Elsenhans, V.D., Leiman, S.M., Owen, O.E., Boden, G. Arch. Intern. Med. (1986) [Pubmed]
  10. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Howard, B.V., Xiaoren, P., Harper, I., Foley, J.E., Cheung, M.C., Taskinen, M.R. Am. J. Med. (1985) [Pubmed]
  11. Effects of tolazamide and exogenous insulin on pattern of postprandial carbohydrate metabolism in patients with non-insulin-dependent diabetes mellitus. Results of randomized crossover trial. Firth, R., Bell, P., Marsh, M., Rizza, R.A. Diabetes (1987) [Pubmed]
  12. Differential activities of tolbutamide, tolazamide, and glyburide in vitro on rabbit myocardial membrane Ca2+-transporting ATPase activity. Warnick, P.R., Davis, F.B., Davis, P.J., Mylotte, K.M., Blas, S.D. Diabetes (1986) [Pubmed]
  13. The pharmacology of sulfonylureas. Skillman, T.G., Feldman, J.M. Am. J. Med. (1981) [Pubmed]
  14. Processing and transport of insulin by vascular endothelial cells. Effects of sulfonylureas on insulin receptors. King, G.L., Johnson, S.M., Jialal, I. Am. J. Med. (1985) [Pubmed]
  15. Effect of tolazamide on basal ketogenesis, glycogenesis, and gluconeogenesis in liver obtained from normal and diabetic rats. McCormick, K., Williams, M.C., Sicoli, R., Chen, L. Endocrinology (1986) [Pubmed]
  16. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Salhanick, A.I., Konowitz, P., Amatruda, J.M. Diabetes (1983) [Pubmed]
  17. Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Asano, K., Cortes, P., Garvin, J.L., Riser, B.L., Rodríguez-Barbero, A., Szamosfalvi, B., Yee, J. Kidney Int. (1999) [Pubmed]
  18. Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines. Shroff, J.R., Elpern, B., Kobrin, S., Cervoni, P. J. Med. Chem. (1982) [Pubmed]
  19. Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere. Selvaag, E. Photodermatology, photoimmunology & photomedicine. (1996) [Pubmed]
  20. 2-Deoxyglucose tissue levels and insulin levels following tolazamide dosing in normal and obese mice. Skillman, C.A., Fletcher, H.P. Exp. Clin. Endocrinol. (1986) [Pubmed]
  21. Gastric inhibitory polypeptide hypersecretion in diabetes mellitus: effect of sulfonylurea treatment. Coxe, J.S., O'Dorisio, T.M., Cataland, S., Crockett, S.E. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  22. Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy. Mukherjee, A.B., Ghazanfari, A., Svoronos, S., Staton, R.C., Nakada, T., Kwee, I.L. Neurology (1986) [Pubmed]
  23. Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Szabó, C., Salzman, A.L. Shock (1996) [Pubmed]
  24. Metabolic fate of tolazamide in man and in the rat. Thomas, R.C., Duchamp, D.J., Judy, R.W., Ikeda, G.J. J. Med. Chem. (1978) [Pubmed]
  25. Altering therapy of type II diabetes mellitus from insulin to tolazamide increases blood pressure in spite of weight loss. Schmitt, J.K., Johns, S.B. Am. J. Hypertens. (1995) [Pubmed]
  26. Adjunctive use of tolazamide in newly-diagnosed diabetic children. Sanders, R., Faro, B., Stoler, P., Mick, G.J., McCormick, K.L. Horm. Metab. Res. (1990) [Pubmed]
  27. Tolazamide-induced cholestasis. Bridges, M.E., Pittman, F.E. South. Med. J. (1980) [Pubmed]
WikiGenes - Universities